INS and Hypoglycemia: Historically, glucose lowering agents approved for management of T2D in patients with advanced CKD have been limited to insulin and sulfonylureas despite their associated risk of hypoglycemia and neutral effect on cardiovascular outcomes or progression of kidney disease9.